Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells

Acharaporn Duangjai, Kui Luo, Yan Zhou, Jiyuan Yang, Jindřich Kopeček

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

Multiblock, backbone degradable HPMA copolymer-drug conjugates containing gemcitabine and DACH platinum (mP-GEM and mP-DACH Pt), respectively were synthesized by reversible addition-fragmentation chain transfer (RAFT) polymerization and subsequent chain extension by click chemistry. Using combination index analysis, the cytotoxicities of the two multiblock conjugates, as single agent and in combination, were evaluated in vitro in A2780 human ovarian cancer cells, with free drugs as controls. The greatest synergistic cytotoxic effect was observed when A2780 cells were sequentially exposed to mP-GEM for 24 h and mP-DACH Pt for 48 h. In addition, mechanistic studies support the rationale of the synergy between mP-GEM and mP-DACH Pt: mP-GEM pretreatment was able to enhance the platinum-DNA adduct accumulation and inhibit cell proliferation to a higher extent than single mP-DACH Pt treatment. These observations are useful for the development of combination macromolecular therapeutics for ovarian cancer based on the second-generation backbone degradable HPMA copolymers.

Original languageEnglish (US)
Pages (from-to)187-196
Number of pages10
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume87
Issue number1
DOIs
StatePublished - May 2014
Externally publishedYes

Keywords

  • Biodegradable polymers
  • Combination therapy
  • DACH Pt
  • Gemcitabine
  • HPMA copolymers
  • Ovarian cancer

Fingerprint

Dive into the research topics of 'Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells'. Together they form a unique fingerprint.

Cite this